Cite
HARVARD Citation
Kelly, R. et al. (2015). Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].